|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-1.18/-0.61
|
企業價值
752.35M
|
資產負債 |
每股賬面淨值
2.48
|
現金流量 |
現金流量率
--
|
損益表 |
收益
53.76M
|
每股收益
0.18
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/16 15:46 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GSK to develop a second-generation covid vaccine. CureVac's first attempt to develop a covid vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipelinecandidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases. |